Terms: = Pancreatic cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
6 results:
1. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of clinical outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract] [Full Text] [Related]
2. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of pancreatic Ductal Adenocarcinoma.
Al-Zoughbi W; Schauer S; Pichler M; Hoefler G
Pathobiology; 2018; 85(5-6):342-347. PubMed ID: 30227407
[TBL] [Abstract] [Full Text] [Related]
3. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract] [Full Text] [Related]
4. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract] [Full Text] [Related]
5. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
[TBL] [Abstract] [Full Text] [Related]
6. Expression of p16(ink4a) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Chang DT; Chapman CH; Norton JA; Visser B; Fisher GA; Kunz P; Ford JM; Koong AC; Pai RK
Cancer; 2010 Nov; 116(22):5179-87. PubMed ID: 20665497
[TBL] [Abstract] [Full Text] [Related]
